drugset / Trial / NCT06963346
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
Phase 1
Suspended
12 enrolled
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
In this study, we aim to evaluate the safety and efficacy of neoadjuvant combination using intravesical romidepsin and durvalumab in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC).
Timeline
- Start
- 2025-06-24
- Primary completion
- 2028-04
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Other |
| Subject | Romidepsin | Peptide | 0.2 ng/ml | Other |
| Subject | Romidepsin | Peptide | 0.4 ng/ml | Other |
| Subject | Romidepsin | Peptide | 2 unknown | Other |